These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24304421)

  • 21. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
    Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y
    Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
    Diamond JM; de Almeida AM; Belo HJ; da Costa MP; Cabeçadas JM; Abecasis MM
    Ann Hematol; 2016 Dec; 95(12):2101-2104. PubMed ID: 27699446
    [No Abstract]   [Full Text] [Related]  

  • 23. Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
    Basak G; Torosian T; Snarski E; Niesiobedzka J; Majewski M; Gronkowska A; Urbanowska E; Jedrzejczak W
    Ann Transplant; 2010; 15(2):68-70. PubMed ID: 20657522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
    Khorashad JS; Thelwell N; Milojkovic D; Marin D; Watson JA; Goldman JM; Apperley JF; Foroni L; Reid AG
    J Clin Pathol; 2008 Jul; 61(7):863-5. PubMed ID: 18587017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
    Young PE; Kanagal-Shamanna R; Hu S; Tang G; Thakral B; Daver N; Issa GC; Medeiros LJ; Konoplev S
    Leuk Res; 2021 Dec; 111():106685. PubMed ID: 34438119
    [No Abstract]   [Full Text] [Related]  

  • 27. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.
    Parker WT; Phillis SR; Yeung DT; Hughes TP; Scott HS; Branford S
    Blood; 2014 Jul; 124(1):153-5. PubMed ID: 24993880
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR
    Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of analysis of BCR- ABL kinase domain mutation in chronic myeloid leukemia patients].
    Jin J; Yin X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):95-7. PubMed ID: 24606643
    [No Abstract]   [Full Text] [Related]  

  • 36. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
    Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J
    Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707
    [No Abstract]   [Full Text] [Related]  

  • 37. Detection of ABL1 kinase mutations in Philadelphia-positive patients exhibiting an inadequate molecular response using restriction fragment mass polymorphism and its clinical significance: a single-center experience in Korea.
    Cho YU; Kim SO; Chi HS; Park SJ; Jang S; Park CJ; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ; Hong SP
    Int J Lab Hematol; 2013 Dec; 35(6):589-600. PubMed ID: 23575252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
    Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.
    Minervini CF; Cumbo C; Orsini P; Anelli L; Zagaria A; Impera L; Coccaro N; Brunetti C; Minervini A; Casieri P; Tota G; Russo Rossi A; Specchia G; Albano F
    Exp Mol Pathol; 2017 Aug; 103(1):33-37. PubMed ID: 28663031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first report of chronic myelogenous leukemia with e19a2 micro-BCR/ABL1 presenting with massive myelofibrosis.
    Kim HY; Park S; Kim SH; Kim HJ
    Blood Cells Mol Dis; 2017 Jun; 65():68-70. PubMed ID: 28571780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.